The company today announced another step forward in the international adoption of its ground-breaking GliaSite radiation therapy system with the first order shipments to Germany. In addition to the orders, IsoRay reported that inquiries from Europe continue to grow. In addition to Germany, the company said it has received inquiries from Italy, Austria, Switzerland and the United Kingdom.
The GliaSite system is the world’s only liquid radiation balloon catheter device used in the treatment of brain cancers. It gives physicians the ability to directly place a specified dosage of liquid radiation in areas where cancer is most likely to remain after completion of brain tumor removal. This leads to a less likelihood for damage to occur to healthy brain tissue when compared to other alternative treatments. GliaSite also diminishes the ability of the brain tumor to recur.
Additionally, IsoRay remarked that it has received an increasing number of inquiries from the international medical community about its Cesium-131 seed sutured mesh for the treatment of a wide array of cancers throughout the body. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life, which gives it unequaled speed in giving off therapeutic radiation.
For further information about IsoRay and its products, please visit the company’s website at www.isoray.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
